Committee approves ban on pay‑for‑delay drug deals to preserve generic access
Loading...
Summary
Senate Bill S3203, which would ban pay‑for‑delay arrangements that keep generics off the market, was reported to first reading after committee discussion about prevalence and patient impacts; sponsor named as Senator Fernandez.
The committee reported Senate Bill S3203 to first reading. The bill, introduced by Senator Fernandez, would amend the Public Health Law to prohibit pay‑for‑delay agreements in which brand manufacturers pay generic manufacturers to delay market entry.
Committee discussion included questions about how common such agreements are and their impact on drug affordability. Committee member Sarah Wright asked, "How prevalent is this?" and proponents on the record said such arrangements do occur and can meaningfully affect patients who depend on affordable generics.
Senator Ryan moved the bill and Senator May seconded. The committee approved the measure by voice vote and reported it to first reading. The transcript contains no roll‑call tally or sponsor testimony beyond the bill description.
Next steps: the bill advances to first reading where additional debate or amendments could be scheduled.
